Shots:
ARCH Venture Partners is a leading US-based venture capital firm recognized for backing bold science and building category-defining companies across biotechnology, life sciences, and transformational healthcare, with a strong focus on company creation
In 2024, ARCH completed 31 investments from Seed to Series A–F and beyond, including late-stage and private rounds. The firm backed innovators such…
Shots:
Welcome to the October edition of Know Your Investor, spotlighting leading investors shaping the future of healthcare and life sciences
This month, we feature Google Ventures (GV), the venture capital arm of Alphabet. GV actively invests across seed to growth-stage companies, spanning sectors such as software, internet, healthcare, life sciences, and artificial intelligence
For…
Shots:
Areteia Therapeutics has reported P-III (EXHALE-4) trial data assessing dexpramipexole (75 or 150mg, PO, BID) vs PBO as an add-on therapy to treat pts (n=600; ≥12yrs.) with inadequately controlled moderate-to-severe asthma & blood AEC ≥300 cells/μL
Trial showed that 150mg improved lung function over Wks. 20 & 24 (1EP), as measured by pre-BD FEV1…
Shots:
An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among others
Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…

